Analytical Data
-
基因名
SLC25A15
- Application
-
别名
Solute carrier family 25 member 15
-
种属
Human
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y619
-
表达区间
1-301aa
-
分子量
59.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC25A15, also known as the mitochondrial ornithine transporter, is a crucial protein encoded by the SLC25A15 gene, which plays a significant role in the urea cycle and amino acid metabolism. The importance of SLC25A15 lies in its function of transporting ornithine across the mitochondrial membrane, facilitating the conversion of ammonia into urea in the liver and supporting various metabolic pathways. Research on SLC25A15 has gained momentum due to its association with several metabolic disorders, particularly hyperornithinemia-hyperammonaemia-homocitrullinuria syndrome (HHH syndrome), a genetic condition characterized by elevated levels of ornithine and ammonia in the bloodstream, leading to neurological complications. Understanding the structure and function of SLC25A15, including the dynamics of its transport mechanism, is critical for deciphering its biological role and the pathophysiology of related diseases. The recombinant expression of SLC25A15 in heterologous systems allows for detailed biochemical studies, providing insights into its substrate specificity, transport kinetics, and potential regulatory mechanisms. Additionally, characterizing the recombinant protein can lead to the identification of novel therapeutic targets and the development of strategies to mitigate the effects of associated metabolic disorders. Overall, the investigation of SLC25A15 recombinant protein is pivotal in bridging the gap between molecular biology and clinical applications, aiming at improving the understanding and treatment options for patients affected by conditions linked to this important transporter.












